Human Milk Oligosaccharides (HMO) Market Report Scope & Overview:

The Human Milk Oligosaccharides (HMO) Market was valued at USD 0.69 Billion in 2025 and is expected to reach USD 6.70 Billion by 2035, growing at a CAGR of 25.50% from 2026 to 2035.

The Human Milk Oligosaccharides (HMO) market is growing rapidly because there are over 200 HMO structures present in the human breast milk that aid immunity, the development of microbiota, and gut health. HMO are carbohydrates found in human breast milk that function as prebiotics that assist in the growth of probiotics, help in building up the infant’s immune system and digestive system. The advantages include protection from pathogens and reduction in chances of infections. In addition to that, market growth is driven by the transition to microbiome-based nutrition across more than 46 nations, biotechnology-enabled fermentation contributing an increased share to the total production of HMOs, and the increasing demand for high-end infant formula products similar to the health benefits of breast milk.

Clinical studies show HMOs improve gut flora diversity by 28%, supporting expanded use in infant formula, functional foods, and dietary supplements, as commercial production increasingly focuses on 2'-FL, 3-FL, LNT, LNnT, and other complex HMOs that collectively represent over 82% of global demand across the broader human milk oligosaccharides ingredient category.

To Get more information Human Milk Oligosaccharides (HMO) Market - Request Free Sample Report

Human Milk Oligosaccharides (HMO) Market Trends

• Rising adoption of HMO-infused functional drinks is expanding applications beyond infant nutrition into adult gut-health beverages.
• Growing use of precision fermentation is enabling scalable, consistent, and cost-efficient HMO production.
• Increasing premium nutrition demand is driving HMO-enriched product launches across infant formula and functional foods.
• Expanding clinical research is strengthening evidence for HMO benefits and supporting broader regulatory and consumer acceptance.
• Strategic partnerships are enabling development of diverse HMO applications across infant formula, functional foods, and beverages.

The U.S. Human Milk Oligosaccharides (HMO) Market Outlook

The U.S. Human Milk Oligosaccharides (HMO) Market was valued at USD 0.18 Billion in 2025 and is projected to reach USD 1.76 Billion by 2035, growing at a CAGR of 25.50% during 2026–2035.

Manufacturers of infant formula and functional beverages, who are considered among the most dominant in the country, keep on increasing the use of HMOs products due to increased awareness among parents about the nutrition of infants as well as the benefits of using HMOs in the development of healthy gut and immune systems of babies. Functional drinks containing HMOs have found a new place in the local market, changing their trajectory from infant formula to adult drinks of nutrition and wellness.

In 2025, the U.S. Human Milk Oligosaccharides (HMO) Market continued to expand as infant nutrition manufacturers increased HMO incorporation in response to growing awareness of their gut-health and immune-support benefits. Rising interest in functional nutrition is also extending HMO applications beyond infant formula into adult wellness products and functional beverages. Increasing investment in biotechnology-based HMO production and product innovation by leading nutrition companies is further supporting the development of the U.S. market.

Human Milk Oligosaccharides (HMO) Market Segment Analysis

• By Type, 2’FL dominated the human milk oligosaccharides (HMO) market with a 56.80% share in 2025, while 3’FL is the fastest-growing type segment with a CAGR of approximately 22.00% from 2026–2035.
• By Application, infant formula dominated the human milk oligosaccharides (HMO) market with a 76.00% share in 2025, while functional foods & adult nutrition is the fastest-growing application segment with a CAGR of 29.60% from 2026–2035.
• By Distribution Channel, drug store/pharmacy dominated the human milk oligosaccharides (HMO) market with a 46.80% share in 2025, while hypermarkets & supermarkets is the fastest-growing distribution channel segment with a CAGR of 22.90% from 2026–2035.
• By Production Technology, microbial/biotechnology fermentation dominated the human milk oligosaccharides (HMO) market with a 71.00% share in 2025, while chemical synthesis is the fastest-growing production technology segment with a CAGR of 24.60% from 2026–2035.

By Type, 2'-FL dominated the human milk oligosaccharides (HMO) market, while 3’-FL is the fastest-growing segment.

2'-Fucosyllactose (2'-FL) is the dominant player in the human milk oligosaccharides (HMOs) market because of its widespread commercialization in infant formulas and its regulatory acceptance in the key markets. The close resemblance of 2'-FL to natural HMOs found in breast milk, along with its proven ability to help establish healthy microflora in infants' guts, is another reason for its widespread application in infant nutrition. The rise in investments by the producers of HMOs into fermentation technology and the growing presence of 2'-FL in premium infant formulas contribute to this trend.

3'-fucosyllactose (3'-FL) is emerging as the fastest growing variety of HMOs, as manufacturers increasingly venture outside the existing HMOs and produce a wider range of oligosaccharides. The rising adoption of 3'-FL in next generation infant formulations has been backed up by ongoing scientific studies on the potential probiotic effects of 3'-FL. Better precision fermentation and microbial production technologies have also enabled better manufacturing capabilities for 3'-FL. With more approvals and the demand for differentiated infant formulas that mimic human milk on the rise, demand for 3'-FL will increase further.

By Application, Infant Formula dominated the Human Milk Oligosaccharides (HMO) Market, while functional foods & adult nutrition is the fastest-growing segment.

Applications analysis indicates that the infant formula applications hold 76% market share by 2025. The infant formula applications are still the leading application categories because of the critical role played by HMOs in mimicking the effects of breast milk with its prebiotic properties, thus forming the base applications.

The functional foods & adult nutrition segment is expected to register the fastest CAGR of 29.60% during the forecast period 2026-2035. HMO-infused functional drinks have newly found ground, shifting course from infant formula to adult nutrition and wellness drinks, including ready-to-drink gut-health beverages and immune-boosting shakes gaining traction among health-conscious adult consumers.

By Distribution Channel, drug store/pharmacy dominated the human milk oligosaccharides (HMO) market, while hypermarkets & supermarkets is the fastest-growing segment.

Drug Store/Pharmacy was the dominating segment in the human milk oligosaccharides market due to the existing channel for the distribution of infant formula which includes pharmacies and specialty retailers who have been traditionally turning to for professional advice on infant nutrition.

The hypermarkets & supermarkets segment is expected to register a robust CAGR of 22.90% during the forecast period, primarily driven by the increasing consumer preference for convenient, in-store shopping experiences. Growing HMO-enriched product availability across mainstream retail channels is driving rising segment growth as manufacturers expand distribution beyond traditional pharmacy-focused infant formula sales.

By Production Technology, microbial/biotechnology fermentation dominated the human milk oligosaccharides (HMO) market, while chemical synthesis is the fastest-growing segment.

Biotechnology process is responsible for generating 71% of all HMOs. Fermentation using microbes is the preferred production method because of its efficient scalability and cost efficiency, coupled with its capability to create HMO structures with high levels of purity, thus making it the preferred production method for most HMO producers around the globe.

The chemical synthesis segment is expected to register a CAGR of 24.60% during the forecast period 2026-2035. Growing demand for specific, structurally precise HMO compounds not yet achievable through fermentation at commercial scale is driving continued chemical synthesis investment, particularly for specialty applications requiring the highest purity and structural specificity.

Regional Analysis

North America Human Milk Oligosaccharides Market Insights

The North America HMO Market held a significant regional market share in 2025 owing to strong consumer awareness of infant nutritional needs and growing HMO-infused functional drink adoption expanding beyond infant formula into adult wellness applications.

The US was the leading country within the North America HMO Market in 2025, set to exhibit high consumption growth with a CAGR of 4.8% through 2035, as leading nutrition companies expand HMO-infused functional drink categories. Canada is contributing to regional growth through its own expanding infant nutrition and functional beverage retail sector.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Human Milk Oligosaccharides Market Insights

The Europe region was the leading revenue contributor in the global HMOs market in 2025 owing to the region's significant infant formula manufacturing facilities, strict regulations validating HMO ingredients' safety, and established premium infant nutrition consumers' culture in the region.

Germany is one of the key players in the Europe region due to its presence of significant infant formula manufacturing facility and increasing demands from the consumers towards the premium and natural infant nutrition. Some other regions like The Netherlands, which has Royal FrieslandCampina, and Denmark, which has Glycom, are also making significant contribution towards the market growth by manufacturing HMOs in large quantities.

Asia Pacific Human Milk Oligosaccharides Market Insights

Asia Pacific is expected to register the fastest regional CAGR during the forecast period 2026-2035, driven by the region's growing population and increasing birth rates, particularly in countries such as China and India, alongside expanding domestic infant formula manufacturing capacity.

China is one of the main growth drivers in the Asia Pacific HMO Market, owing to its massive infant population and rapidly growing demand for premium infant formula products. India and Southeast Asian nations are also contributing to regional growth through expanding infant nutrition manufacturing capacity and rising consumer awareness of HMO benefits.

Middle East & Africa and Latin America Human Milk Oligosaccharides Market Insights

Middle East & Africa and Latin American regions are gradually expanding HMO adoption as infant formula retail infrastructure develops and consumer awareness of premium infant nutrition benefits grows across both regions.

Brazil is set to be a prominent Latin American market fueled by growing infant formula manufacturing capacity and rising consumer demand for premium, natural infant nutrition products. The Middle East & Africa region has UAE and Saudi Arabia investing in modern retail infrastructure that is gradually expanding access to premium HMO-enriched infant formula categories.

Market Dynamics

Growth Drivers: Rising infant nutrition science and microbiome awareness driving market growth

The global trend towards microbiome nutrition has fueled the acceptance of HMOs among over 46 countries worldwide due to the increased clinical and scientific evidences of the efficacy of HMOs in gut health and immunity. The increase in the number of infants remains a key factor, which is sustained by the rise in the birth rates, resulting in demand for products that mimic the health benefits of human breast milk.

Increased trends of premium infant formulas and growing preference for natural and bioactive ingredients among consumers have continued to support the demand for HMOs as their status as a leading functional ingredient continues to grow due to validation from research. Other factors supporting the demand during the forecast period include technological advances in production of HMOs, which make them more easily available for use in health and wellness products; growing demand for functional foods and supplements; and HMOs-based functional drinks for adults.

Restraints: Regulatory approval complexity and high production costs limiting market expansion

One of the main barriers to market growth is regulatory approvals, because HMOs are novel bioactive ingredients that must undergo rigorous safety, quality, and efficacy evaluations before they can be approved for use in infant formula, dietary supplements, and functional foods across different international jurisdictions.

Additionally, the substantial cost associated with both fermentation-based and chemical synthesis HMO production continues to constrain broader market penetration, particularly for smaller manufacturers seeking to compete against established, well-capitalized ingredient suppliers. The technical complexity of scaling precision fermentation to produce structurally diverse HMO compounds at commercial volumes further requires substantial ongoing research and development investment.

Opportunities: Expansion of adult nutrition applications and fermentation technology creating new growth avenues

HMO-infused functional drinks have newly found ground in adult nutrition and wellness markets, shifting course from infant formula to ready-to-drink gut-health beverages, immune-boosting shakes, and metabolic wellness drinks, creating substantial opportunities for manufacturers capable of developing differentiated adult nutrition product formulations.

There is a considerable growth opportunity in the continued development of biotechnology-driven fermentation technology enabling more efficient, scalable production of diverse HMO structures. The expansion of infant formula manufacturing capacity and microbiome-based nutrition awareness in emerging markets across Asia Pacific and Latin America is likely to unlock substantial new demand throughout the forecast period.

Recent Developments:

• 2025: Abbott expanded its HMO-infused functional beverage product line, targeting adult gut health and immune wellness applications beyond its traditional infant formula portfolio.
• 2025: dsm-firmenich, through its Glycom business, expanded its fermentation-based HMO production capacity, strengthening its ability to supply growing global demand for diverse HMO structures.
• 2026: Chr. Hansen, through Jennewein Biotechnologie, launched a new HMO ingredient blend designed for premium infant formula applications, offering manufacturers enhanced structural diversity closely mimicking breast milk composition.
• 2026: Inbiose NV expanded its precision fermentation HMO manufacturing facility, strengthening its position supplying scalable, high-purity HMO ingredients to infant formula and functional food customers.

Human Milk Oligosaccharides (HMO) Market key players are:

• Abbott Laboratories
• Inbiose NV
• Glycom A/S (dsm-firmenich)
• Chr. Hansen Holding A/S (Jennewein Biotechnologie)
• Elicityl S.A.
• ZuChem, Inc.
• Biosynth Carbosynth
• Dextra Laboratories Ltd.
• IFF (DuPont Nutrition & Biosciences)
• Glycosyn
• BASF SE
• Nestle Health Science
• Neolacta Lifesciences Pvt. Ltd.
• dsm-firmenich (Royal DSM)
• Medolac Laboratories
• Royal FrieslandCampina N.V.
• Kyowa Hakko Bio Co., Ltd.
• Jennewein Biotechnologie GmbH
• Suntory Holdings Limited
• Glycom

Human Milk Oligosaccharides (HMO) Market Report Scope :